Etiology and clinical features of non-O1/non-O139 Vibrio cholerae infection in an inland city in China.
Journal
Biomolecules & biomedicine
ISSN: 2831-090X
Titre abrégé: Biomol Biomed
Pays: Bosnia and Herzegovina
ID NLM: 9918522188506676
Informations de publication
Date de publication:
03 Jul 2023
03 Jul 2023
Historique:
received:
04
01
2023
accepted:
06
02
2023
medline:
5
7
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
epublish
Résumé
Non-O1/non-O139 Vibrio cholerae (NOVC) causes various illnesses ranging in severity from mild to life-threatening but were ignored previously. Knowledge of the NOVC infection, particularly bacteremia, is limited because of its rarity. Here we first retrospectively reported the demographic, clinical, and therapy characteristics of patients with NOVC infection. Isolated NOVC stains were identified by a series of biochemical, mass spectrometry (MS), and serum agglutination tests. The results of 11 patients with NOVC infection (including 8 with bacteremia) with a median age of 68 years were included in this report. Most isolated NOVC strains had antibiotic susceptibility. Patients with NOVC-positive were distributed in various departments, most occurring in gastroenterology (6 cases). Hepatic disease was the most common comorbid disease, followed by diabetes (3 cases) and biliary tract disease (3 cases). Two cases were previously healthy. The most common symptom at presentation was fever. All patients presented with abnormal changes in hematology and inflammatory parameters. Cephalosporins were the most frequently used antibiotics. Ten patients had a favorable outcome after treatment; one died from complicated underlying diseases. In summary, we recommend the timely identification of NOVC strains using MALDI-TOF-MS. The suspicion of NOVC bacteremia cannot be ruled out regardless of the host's immune status. An alternative therapeutic regimen for this infection may be β-lactam antibiotics or combined with β-lactamase inhibitors. Regardless, the specific therapeutic regimen should be based on the antibiogram data.
Identifiants
pubmed: 36815436
doi: 10.17305/bb.2022.8745
pmc: PMC10351102
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
698-704Références
Infection. 2017 Apr;45(2):237-240
pubmed: 27837335
Front Microbiol. 2019 Apr 12;10:733
pubmed: 31031724
Infect Drug Resist. 2020 Apr 07;13:1009-1016
pubmed: 32308442
Vaccine. 2020 Feb 29;38 Suppl 1:A63-A72
pubmed: 31279566
Appl Environ Microbiol. 2015 Mar;81(6):1909-18
pubmed: 25556194
J Clin Microbiol. 2014 Oct;52(10):3819-21
pubmed: 25122858
Acta Clin Belg. 2018 Dec;73(6):462-464
pubmed: 29916306
Rev Argent Microbiol. 2011 Apr-May;43(2):81-3
pubmed: 21731967
J Clin Microbiol. 2015 May;53(5):1741-4
pubmed: 25740773
Case Rep Infect Dis. 2012;2012:698746
pubmed: 22830064
Springerplus. 2015 Oct 05;4:575
pubmed: 26543710
J Clin Microbiol. 2000 Sep;38(9):3518-9
pubmed: 10970422
J Basic Microbiol. 2009 Dec;49(6):538-44
pubmed: 19810041
Front Public Health. 2019 Jul 23;7:203
pubmed: 31396501
IDCases. 2019 Mar 27;15:e00527
pubmed: 30989053
BMC Microbiol. 2013 Mar 04;13:52
pubmed: 23497008
Travel Med Infect Dis. 2007 Jan;5(1):44-6
pubmed: 17161319
Infect Drug Resist. 2020 Apr 01;13:941-947
pubmed: 32280250
J Med Microbiol. 2010 Oct;59(Pt 10):1260-1262
pubmed: 20616193
Am J Gastroenterol. 1996 Feb;91(2):336-40
pubmed: 8607503
Environ Microbiol. 2020 Oct;22(10):4342-4355
pubmed: 32337781
J Infect Public Health. 2018 Sep - Oct;11(5):601-604
pubmed: 29366858
Lancet. 2017 Sep 23;390(10101):1539-1549
pubmed: 28302312
Epidemiol Infect. 2020 Jul 08;148:e186
pubmed: 32635946
Vaccine. 2020 Feb 29;38 Suppl 1:A83-A92
pubmed: 31272870
Heliyon. 2018 Dec 17;4(12):e01040
pubmed: 30582054
Int J Infect Dis. 2014 Aug;25:116-8
pubmed: 24905769
J Pak Med Assoc. 2018 Apr;68(4):650-652
pubmed: 29808060